CD276 and neoplasm: Consistent with clinical studies of other DXd-payload ADCs, we showed that target expression was necessary for response, but additional factors clearly impacted this (54,55) as tumour cells remaining after DS-7300a treatment in the two B7-H3 positive PDX models still expressed levels of B7-H3 comparable to that of the parental tumour and control drug treated tumours.